New technologies for the enhancement of skeletal repair

T. William Axelrad, Sanjeev Kakar, Thomas A. Einhorn

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Although fracture healing is a well-optimized biological process that leads to healing, approximately 10-20% of fractures result in impaired or delayed healing and these fractures may benefit from the use of biotechnologies to enhance skeletal repair. Peptide signaling molecules such as the bone morphogenetic proteins have been shown to stimulate the healing of fresh fractures, nonunions, and spinal fusions and side effects from their use appear to be minimal. Other growth factors currently being studied for local application include growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ), and platelet-derived growth factor (PDGF). Molecules such as prostaglandin E receptor agonists and the thrombin-related peptide, TP508, have shown promise in animal models of fracture repair. Gene therapy using various growth factors or combinations of factors might also aid in fracture repair, particularly as new methods for delivery that do not require viral vectors are developed. Systemic therapy with agents such as parathyroid hormone (PTH), growth hormone (GH), and the HMG-CoA reductase inhibitors are also under investigation. As these and other technologies are shown to be safe and effective, their use will become a part of the standard of care in managing skeletal injuries.

Original languageEnglish (US)
JournalInjury
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Biomedical Enhancement
Fracture Healing
Intercellular Signaling Peptides and Proteins
Growth Differentiation Factor 5
Prostaglandin E Receptors
Biological Phenomena
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Spinal Fusion
Bone Morphogenetic Proteins
Platelet-Derived Growth Factor
Transforming Growth Factors
Standard of Care
Biotechnology
Parathyroid Hormone
Genetic Therapy
Vascular Endothelial Growth Factor A
Growth Hormone
Animal Models
Technology
Peptides

Keywords

  • Bone morphogenetic protein
  • EP2 receptor agonist
  • EP4 receptor agonist
  • Fracture repair
  • Gene therapy
  • HMG-CoA reductase inhibitors
  • Nonunion
  • Parathyroid hormone
  • Platelet-derived growth factor
  • TP508
  • Transforming growth factor β
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Emergency Medicine
  • Orthopedics and Sports Medicine

Cite this

New technologies for the enhancement of skeletal repair. / William Axelrad, T.; Kakar, Sanjeev; Einhorn, Thomas A.

In: Injury, Vol. 38, No. SUPPL. 1, 03.2007.

Research output: Contribution to journalArticle

William Axelrad, T. ; Kakar, Sanjeev ; Einhorn, Thomas A. / New technologies for the enhancement of skeletal repair. In: Injury. 2007 ; Vol. 38, No. SUPPL. 1.
@article{926139a9756d4622a1560f5cf05373eb,
title = "New technologies for the enhancement of skeletal repair",
abstract = "Although fracture healing is a well-optimized biological process that leads to healing, approximately 10-20{\%} of fractures result in impaired or delayed healing and these fractures may benefit from the use of biotechnologies to enhance skeletal repair. Peptide signaling molecules such as the bone morphogenetic proteins have been shown to stimulate the healing of fresh fractures, nonunions, and spinal fusions and side effects from their use appear to be minimal. Other growth factors currently being studied for local application include growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ), and platelet-derived growth factor (PDGF). Molecules such as prostaglandin E receptor agonists and the thrombin-related peptide, TP508, have shown promise in animal models of fracture repair. Gene therapy using various growth factors or combinations of factors might also aid in fracture repair, particularly as new methods for delivery that do not require viral vectors are developed. Systemic therapy with agents such as parathyroid hormone (PTH), growth hormone (GH), and the HMG-CoA reductase inhibitors are also under investigation. As these and other technologies are shown to be safe and effective, their use will become a part of the standard of care in managing skeletal injuries.",
keywords = "Bone morphogenetic protein, EP2 receptor agonist, EP4 receptor agonist, Fracture repair, Gene therapy, HMG-CoA reductase inhibitors, Nonunion, Parathyroid hormone, Platelet-derived growth factor, TP508, Transforming growth factor β, Vascular endothelial growth factor",
author = "{William Axelrad}, T. and Sanjeev Kakar and Einhorn, {Thomas A.}",
year = "2007",
month = "3",
doi = "10.1016/j.injury.2007.02.010",
language = "English (US)",
volume = "38",
journal = "Injury",
issn = "0020-1383",
publisher = "Elsevier Limited",
number = "SUPPL. 1",

}

TY - JOUR

T1 - New technologies for the enhancement of skeletal repair

AU - William Axelrad, T.

AU - Kakar, Sanjeev

AU - Einhorn, Thomas A.

PY - 2007/3

Y1 - 2007/3

N2 - Although fracture healing is a well-optimized biological process that leads to healing, approximately 10-20% of fractures result in impaired or delayed healing and these fractures may benefit from the use of biotechnologies to enhance skeletal repair. Peptide signaling molecules such as the bone morphogenetic proteins have been shown to stimulate the healing of fresh fractures, nonunions, and spinal fusions and side effects from their use appear to be minimal. Other growth factors currently being studied for local application include growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ), and platelet-derived growth factor (PDGF). Molecules such as prostaglandin E receptor agonists and the thrombin-related peptide, TP508, have shown promise in animal models of fracture repair. Gene therapy using various growth factors or combinations of factors might also aid in fracture repair, particularly as new methods for delivery that do not require viral vectors are developed. Systemic therapy with agents such as parathyroid hormone (PTH), growth hormone (GH), and the HMG-CoA reductase inhibitors are also under investigation. As these and other technologies are shown to be safe and effective, their use will become a part of the standard of care in managing skeletal injuries.

AB - Although fracture healing is a well-optimized biological process that leads to healing, approximately 10-20% of fractures result in impaired or delayed healing and these fractures may benefit from the use of biotechnologies to enhance skeletal repair. Peptide signaling molecules such as the bone morphogenetic proteins have been shown to stimulate the healing of fresh fractures, nonunions, and spinal fusions and side effects from their use appear to be minimal. Other growth factors currently being studied for local application include growth and differentiation factor-5 (GDF-5), vascular endothelial growth factor (VEGF), transforming growth factor β (TGFβ), and platelet-derived growth factor (PDGF). Molecules such as prostaglandin E receptor agonists and the thrombin-related peptide, TP508, have shown promise in animal models of fracture repair. Gene therapy using various growth factors or combinations of factors might also aid in fracture repair, particularly as new methods for delivery that do not require viral vectors are developed. Systemic therapy with agents such as parathyroid hormone (PTH), growth hormone (GH), and the HMG-CoA reductase inhibitors are also under investigation. As these and other technologies are shown to be safe and effective, their use will become a part of the standard of care in managing skeletal injuries.

KW - Bone morphogenetic protein

KW - EP2 receptor agonist

KW - EP4 receptor agonist

KW - Fracture repair

KW - Gene therapy

KW - HMG-CoA reductase inhibitors

KW - Nonunion

KW - Parathyroid hormone

KW - Platelet-derived growth factor

KW - TP508

KW - Transforming growth factor β

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33947305613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947305613&partnerID=8YFLogxK

U2 - 10.1016/j.injury.2007.02.010

DO - 10.1016/j.injury.2007.02.010

M3 - Article

C2 - 17383486

AN - SCOPUS:33947305613

VL - 38

JO - Injury

JF - Injury

SN - 0020-1383

IS - SUPPL. 1

ER -